An Interview With Dr. Vallerie McLoughlin, Director of the University of Michigan's Pulmonary Hypertension Program
About this episode
Larry Luxner interviews Dr. Vallerie McLoughlin about a phase 3 trial for ralinepag to treat pulmonary arterial hypertension.
Larry Luxner, senior correspondent for Rare Disease Advisor, interviews Vallerie McLoughlin, MD, director of the Pulmonary Hypertension Program at the University of Michigan-Ann Arbor, about results of a phase 3 trial for ralinepag to treat pulmonary arterial hypertension.
People in this episode
Host: Larry Luxner
Guest: Vallerie McLoughlin
Topics covered
- pulmonary hypertension
- clinical trials
- interview
- healthcare
- rare diseases
Keywords
- pulmonary hypertension
- ralinepag
- clinical trial
- Vallerie McLoughlin
- rare diseases
Mentioned in this episode
Organizations: University of Michigan, Pulmonary Hypertension Program
Products: ralinepag
Places: Michigan, Ann Arbor
More episodes of Rare Care Podcast
- An Interview With Dr. Michelle Ng Gong, New President of the American Thoracic Society
- An Interview With Dr. Andrew Wilson, Scientific Director of the Alpha-1 Foundation
- An Interview With Craig Martin, Founder and CEO of the Orphan Therapeutics Accelerator
- An Interview With Henriette Farkas, Director of the Hungarian Angioedema Reference Center in Budapest
Explore listener stats, chart rankings, contacts and more on the Rare Care Podcast podcast page.